Opthea (OPT)

• Market cap: $856M
• 1 day: 1.28%
• 5 days: 11.65%
• 1 month: 41.48%
• 3 months: 27.52%
• 6 months: 144.93%
• Year to date: 50.68%
• 1 year: 105.17%
• 5 years: -54.80%
• 10 years: -54.80%

About: Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Employees: 34

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

74% more capital invested

Capital invested by funds: $12.2M [Q2] → $21.3M (+$9.03M) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.53% less ownership

Funds ownership: 0.96% [Q2] → 0.42% (-0.53%) [Q3]

22% less funds holding

Funds holding: 9 [Q2] → 7 (-2) [Q3]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 116% upside
• Avg. target: $12 116% upside
• High target: $12 116% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 22% 1-year accuracy 12 / 54 met price target

116% upside $12

Buy Reiterated

29 Jan 2025